Results 1 to 10 of about 349,122 (350)

Endocannabinoids Produced by White Adipose Tissue Modulate Lipolysis in Lean but Not in Obese Rodent and Human

open access: yesFrontiers in Endocrinology, 2021
White adipose tissue (WAT) possesses the endocannabinoid system (ECS) machinery and produces the two major endocannabinoids (ECs), arachidonoylethanolamide (AEA) and 2-arachidonoylglycerol (2-AG).
Chloé Buch   +10 more
doaj   +1 more source

Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study

open access: yesJournal of Translational Medicine, 2020
Background Elevated lipoprotein(a) [Lp(a)] and fibrinogen (Fib) are both associated with coronary artery disease (CAD). The atherogenicity of Lp(a) can be partly due to the potentially antifibrinolytic categories. We hypothesize that patients with higher
Yan Zhang   +15 more
doaj   +1 more source

Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy

open access: yesFrontiers in Nephrology, 2023
ObjectiveThis study assessed the efficacy of INV-202, a novel peripherally restricted cannabinoid type-1 receptor (CB1R) inverse agonist, in a streptozotocin-induced type-1 diabetes nephropathy mouse model.MethodsDiabetes was induced in 8-week-old C57BL6/
Laetitia Jacquot   +12 more
doaj   +1 more source

OBESITY AND DYSLIPIDEMIA IN CHILDREN WITH CHRONIC HEPATITIS [PDF]

open access: yesRomanian Journal of Pediatrics, 2016
Chronic hepatitis association with various types of dyslipidemia is a reality not only for the obese pediatric patient, in which we expect to find hypercholesterolemia and / or hypertriglyceridemias, but also for normal weight children with hepatitis ...
Alice N. Azoicai   +7 more
doaj   +1 more source

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles. [PDF]

open access: yes, 2017
Treatment of dyslipidemia patients with lipid-lowering drugs leads to a significant reduction in low-density lipoproteins (LDL) level and a low to moderate level of increase in high-density lipoprotein (HDL) cholesterol in plasma.
Alderete, Benjamin   +7 more
core   +1 more source

sRAGE and early signs of cardiac target organ damage in mild hypertensives

open access: yesCardiovascular Diabetology, 2019
Background Soluble Receptor for Advanced Glycation End Products (sRAGE) may be considered a marker inversely related to inflammation and its participation has been established in patients with advanced atherosclerotic vascular diseases.
Andrea Maria Maresca   +12 more
doaj   +1 more source

Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a

open access: yesJournal of Translational Medicine, 2020
Background Green tea drinking has been proven to lower lipid and exert cardiovascular protection, while the potential mechanism has not been fully determined.
Chuan-Jue Cui   +8 more
doaj   +1 more source

The Correlation of Dyslipidemia with the Extent of Coronary Artery Disease in the Multiethnic Study of Atherosclerosis. [PDF]

open access: yes, 2018
BackgroundThe extent of coronary artery calcium (CAC) improves cardiovascular disease (CVD) risk prediction. The association between common dyslipidemias (combined hyperlipidemia, simple hypercholesterolemia, metabolic Syndrome (MetS), isolated low high ...
Abd Alamir, Moshrik   +7 more
core   +4 more sources

Statin-related Lichenoid Dermatosis: An Uncommon Adverse Reaction to a Common Treatment

open access: yesEuropean Journal of Case Reports in Internal Medicine, 2018
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are generally safe and well-tolerated drugs that are extensively used for the primary and secondary prevention of atherosclerotic cardiovascular events.
Zsófia Vesza   +2 more
doaj   +1 more source

Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease [PDF]

open access: yes, 2018
OBJECTIVE: To determine the percentage of children with nonalcoholic fatty liver disease (NAFLD) in whom intervention for low-density lipoprotein cholesterol or triglycerides was indicated based on National Heart, Lung, and Blood Institute guidelines.
Adina Alazraki   +112 more
core   +2 more sources

Home - About - Disclaimer - Privacy